

January 31st 2005 – News Release

Neuronova AG Receives a Silent Partnership from tbg Technologie-Beteiligungs-Gesellschaft mbH and Announces Renaming to Affectis Pharmaceuticals AG

Munich, Germany -- Neuronova AG, a biopharmaceutical company developing novel drugs against depression and anxiety, has received a grant of € 750,000 from Germany's tbg Technologie-Beteiligungs-Gesellschaft mbH, a state funding organisation. Furthermore, Neuronova has officially changed its name to Affectis Pharmaceuticals AG. The renaming to Affectis Pharmaceuticals will become effective immediately and is based on a joint decision of the Company's Executive and Supervisory Board.

The funding from tbg will be used to further advance Affectis' internal drug discovery and development programs, in particular the Company's most advanced program against depression which is to enter preclinical studies in 2006.

"In only one year's time, we have successfully promoted our projects from target discovery to lead validation and positioned the Company as a promising and innovative firm offering new therapeutic perspectives for the treatment of depression and anxiety," commented Dr Herbert Stadler, Chief Executive Officer of Affectis Pharmaceuticals AG. "The grant from tbg and the renaming to Affectis Pharmaceuticals underpin the increasing progress of our organisation." ###

Contact for Affectis Pharmaceuticals AG:

Dr. Herbert Stadler, Chief Executive Officer

Tel.: +49 (0)89 30622-653, Fax: +49 (0)89 30622-370, Email: stadler@affectis.com

Affectis Pharmaceuticals AG, Kraepelinstrasse 2, 80804 Munich, Germany

About Affectis Pharmaceuticals AG:

Affectis Pharmaceuticals AG (formerly Neuronova AG) is a biopharmaceutical company implementing novel concepts for the treatment of depression and anxiety. The company has unique capabilities to discover and develop drugs based on pioneering neurological and genetic findings in the field of affective disorders. These drugs address the increasing need for more comprehensive and faster-acting antidepressants with less side-effect. Affectis was founded in 2002 as a spin-off from the renowned Max-Planck-Institute of Psychiatry, a world leader in the field of psychiatric research. A strong team of executives and scientists with long-term industry experience contribute to Affectis' progress. The Company raised its first round of venture financing in late 2003, led by Life Sciences Partners. Affectis is based in Munich. More information at www.affectis.com